Literature DB >> 25189636

Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.

David E Amacher1.   

Abstract

CONTEXT: The definitive standard for the diagnosis of nonalcoholic fatty liver disease (NAFLD) is clinico-pathological correlation, but frequently the only laboratory abnormality is an elevation of serum aminotransferases.
OBJECTIVE: This has resulted in the search for more specific laboratory biomarkers.
METHODS: The literature was searched for novel plasma/serum markers of NAFLD.
RESULTS: Studies reviewed here included histologically-confirmed patients presenting some stage of NAFLD and monitored one or more novel serum/plasma biomarkers.
CONCLUSION: The most promising application of some of these novel biomarkers for the detection and quantification of NAFLD and particularly NASH appears to be in the combination of several into diagnostic panels.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; non-alcoholic steatosis; novel circulating biomarkers; steatohepatitis

Mesh:

Substances:

Year:  2014        PMID: 25189636     DOI: 10.3109/1354750X.2014.958535

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

Review 1.  Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.

Authors:  Lauren Pavlik; Arie Regev; Paul A Ardayfio; Naga P Chalasani
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

Review 2.  Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Lei He; Linfeng Deng; Quan Zhang; Jianli Guo; Jinan Zhou; Wenjian Song; Fahu Yuan
Journal:  Biomed Res Int       Date:  2017-02-23       Impact factor: 3.411

3.  Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway.

Authors:  Wei Chen; Xiaowei Wang; L I Huang; B O Liu
Journal:  Exp Ther Med       Date:  2015-11-17       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.